Hello, and welcome to the annual meeting of stockholders of Amylyx Pharmaceuticals, Inc. Please note that today's meeting is being recorded. During the meeting, we will have a question and answer session. You can submit questions or comments at any time by clicking on the Q&A tab. It is now my pleasure to turn today's meeting over to Joshua Cohen, Co-Chief Executive Officer and Co-Founder of Amylyx Pharmaceuticals. Mr. Cohen, the floor is yours.
Thank you. Good morning. I am Josh Cohen, Co-CEO and Co-Founder of Amylyx Pharmaceuticals, Inc., and I will act as the chairman for this meeting. I am pleased to welcome you to the Amylyx Pharmaceuticals, Inc. 2022 annual meeting of stockholders. Before I call the meeting to order, I would like to note that the meeting will be conducted and the questions will be considered in the manner outlined in the rules of conduct available on the virtual meeting website. Stockholders can submit questions in writing during the meeting through the web interface.
I would also like to introduce you to the members of our board and our executive team who are here with today. The members of the board with me today are Justin Klee, our Director, Co-Chief Executive Officer, and Co-Founder, Dr. George Milne, Isaac Cheng, Paul, and Paul Fonteyne.
The other executive officers of the company with us today are Jim Frates, our Chief Financial Officer, Gina Mazzariello, our Chief Legal Officer and General Counsel, who will act as secretary for this meeting. I would also like to introduce Sarah Albano, Audit Partner, and Kara Seaman, Audit Manager of Deloitte & Touche LLP, the company's independent registered public accounting firm. The meeting will now officially come to order. We propose to proceed with the formal business of this meeting as set forth in the company's 2022 notice of annual meeting and proxy statement. Will the secretary please report at this time with respect to the mailing of the notice of the meeting and the stockholders' list?
Yes. I have at this meeting a complete list of the stockholders of record of the company at the close of business on April 14, 2022, the record date for this meeting, which is and will be available for examination of any stockholder on the virtual meeting website throughout this meeting. I also have with me an affidavit certifying that commencing on April 29, 2022, a notice of internet availability of proxy materials was deposited in the United States Mail to all stockholders of record as of April 14, 2022. The notice provided that stockholders could access and review our proxy materials, including the proxy card, proxy statement, notice of meeting, and 2021 annual report, or alternatively, request a print copy of the proxy materials.
At this time, I'd like to introduce Margaret Olinger, who has been appointed to act as independent inspector of elections at this meeting. Ms. Olinger has taken and subscribed the customary oath of office to execute her duties with strict impartiality, which will be filed with the records of the meeting. Her function is to decide upon the qualification of voters, accept their votes, and when balloting on all measures is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum?
I have been informed by an inspector of elections that proxies have been received for 44,742,824 of the 57,864,186 shares of common stock outstanding on the record date, which represents approximately 77.32% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.
We will now proceed with the formal business of this meeting. The following proposals are to be considered by our stockholders at this meeting. Proposal one is the election of Justin Klee and Isaac Cheng as Class One directors to serve on the board of directors until the 2025 annual meeting of stockholders and until a successor is duly elected and qualified or until his earlier resignation or removal. Proposal two is the ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2022. Mr. Klee, Mr. Cohen, and Mr. Frates were designated as proxies by certain shareholders. Such shares represented by proxy will be voted in accordance with the instructions given.
If no instruction is given, such shares will be voted for the nominees listed in proposal one and for, proposal two. The secretary will now describe the voting procedures.
The time is now 9:05 A.M. Eastern Time on Thursday, June 9, 2022, and the polls are now open for voting on each of the proposals described by the chairman. Voting is by proxy and virtual written ballot. You do not need to vote again if you have already voted your proxy by telephone or by mail or by internet. There is an order of business set out in the agenda so that we can proceed in an orderly and expeditious manner. All discussions should be limited to the proposals that are the subject of this meeting. Will Lindsey Allen, our head of investor relations, please advise if we have any questions?
We have no questions.
Thank you.
If anyone attending the meeting wants to complete the ballot virtually, please do so now. Okay, the time is 9:06 Eastern Time, and the polls are now closed for voting on each matter presented.
May we have the results of the voting?
The report of the inspector of elections covering the proposals presented at this meeting is as follows. Proposal 1, to elect Justin Klee and Isaac Cheng, M.D., as class 1 directors of the company is carried. Proposal 2, the ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company for the year ending December 31, 2022, has been approved.
There being no other business to properly come before this meeting, the formal portion of the meeting is now adjourned. We have a few minutes now to talk about the latest developments at Amylyx. I'd like to turn it over to my fellow Co-Chief Executive Officer and Co-Founder, Justin Klee. Justin.
Thank you, Josh. Hi, everyone. This is Justin Klee, Co-CEO and Co-Founder. Thank you again for joining us today. I wanted to provide a brief business update. Our regulatory files continue under review with Health Canada, FDA, and EMA. There are no updates to share in regards to Health Canada and EMA. We continue to expect to hear the decision from Health Canada this month in June and EMA early next year. We announced last Friday that the FDA extended the PDUFA date to September 29, 2022, as part of a major amendment to allow more time to review additional analyses of data from the company's clinical studies. Our Phase III PHOENIX study in participants with ALS continues recruitment as planned, and we still expect results in the first half of 2024.
Our teams in Canada, the U.S., and Europe continue their preparations for potential launches in each region. We remain steadfast and dedicated to the ALS and broader neurodegenerative disease communities and dedicated to our mission. Thank you.
Thank you for attending the company's 2022 annual meeting of stockholders. I would now like to turn it back to the operator.
This concludes today's meeting. You may now disconnect.